gemcitabine,nimotuzumab, toripalimab

Phase 3Monoclonal antibody

AAir Force Military Medical University, China

gemcitabine,nimotuzumab, toripalimab is one of 34 small molecule programs targeting Locally Advanced. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally AdvancedRecruiting

Locally AdvancedPhase 3

Recruiting

Competition

Competitive Landscape

39 competitors in Locally Advanced

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Approved

12 2

Eloxatin

Teva

Approved

6 3

Camptosar

Pfizer

Approved

2 4

Padcev

Pfizer

Approved

1 5

Adrucil

EElorac, Inc.

Approved

5 6

Taxol

Teva

Phase 3

7 7

Imfinzi

AstraZeneca

Phase 3

4 8

Truqap

AstraZeneca

Phase 3

1 9

Paraplatin

AAvyxa

Phase 3

8 10

Tuoyi

CCoherus Oncology, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Recruiting

Locally Advanced

NCT06026878

Clinical

Trials by Indication[1]

Locally Advanced1 trial

GNT Induction Treatment in Locally Advanced NPC

Recruiting·—·Phase 3·NCT06026878·228 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for gemcitabine,nimotuzumab, toripalimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — gemcitabine,nimotuzumab, toripalimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for gemcitabine,nimotuzumab, toripalimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Air Force Military Medical University, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: AAir Force Military Medical University, China

gemcitabine,nimotuzumab, toripalimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Locally Advanced1 trial

References

Drug Info

Quick Facts

Related News